ArticleJournal of thoracic disease2024
Impact of multimorbidity on risk stratification and prognosis in elderly patients after acute myocardial infarction.
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic Value of the Osaka Prognostic Score for One-Year Mortality in Patients with ST-Segment Elevation Myocardial Infarction: A Retrospective Observational Cohort Study.Journal of clinical medicine · 2026Article
- Beyond the Diagnosis-Personalized Risk Stratification in Contemporary Cardiovascular Medicine.Life (Basel, Switzerland) · 2026Article
- Machine learning-based mortality risk prediction model for elderly diabetic patients with non-ST-segment elevation myocardial infarction using MIMIC-IV database.Scientific reports · 2025Article
- Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI undergoing PCI.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elderly patients with first acute myocardial infarction (AMI) often have serious clinical features and worse prognoses. The purpose of the study was to evaluate the burden of comorbidity in predicting prognosis of elderly patients after AMI. Methods: A total of 479 elderly patients with AMI divided into three groups: group A (with zero or one comorbidity), group B (with two comorbidities), and group C (with three or more comorbidities). The clinical characteristics, medication, in-hospital complications, and one-year prognosis of these patients were collected and compared across the three groups. Results: Compared to group A, the age, heart rate, creatinine and uric acid, glucose, left atrial diameter (LAd), relative number of multi-vessel and culprit vessels located in left main (LM) artery and thrombolysis in myocardial infarction (TIMI) grade 0-1 were significantly higher in groups B and C. Compared to group A, the incidences of in-hospital death, paroxysmal atrial flutter/atrial fibrillation, and acute heart failure were significantly higher in groups B and C and that of in-hospital cardiac rupture was remarkably higher in group C. Compared group A, the incidence of one-year major adverse cardiovascular events (MACEs), all-cause death, and attacks of acute heart failure were significantly higher in groups B and C. The incidences of one-year non-fatal ischemic stroke in group C and late revascularization in group B were dramatically higher. Conclusions: A higher comorbidity burden was associated with more serious clinical presentations, more severe in-hospital complications, and worse one-year prognosis of elderly AMI patients. These findings can help clinicians to identify high-risk elderly AMI patients, determine the prognostic impact of comorbidity, and provide better managements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.